““““““““““““““
Jeffrey M. Kaplan, MD, and Matthew J. Baker, MD, discuss implications of treating patients with relapsing-remitting multiple sclerosis based on a recent study that evaluated time to first qualifying relapse in patients treated with cladribine in CLARITY study followed by placebo in CLARITY extension study.
::::::::::::::::::::::::::::::::::::::;;;;;;;;;;;;;;;;;;;;;::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Information Shared by: MSViewsandNews,
to and for those affected by Multiple Sclerosis
::::::::::::::::::::::::::::::::::::::;;;;;;;;;;;;;;;;;;;;;:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews